TMP778 also blocked IL-17 production by skin mononuclear cells of psoriasis patients and significantly impaired expression of Th17 signature gene from psoriasis patients [78]. In vivo, TMP778 suppressed imiquimod-induced cutaneous inflammation and EAE [77, 78]. This evidence concerns the gene IL17A and psoriasis.